Genzyme Corp and Neozyme Corp have been issued a patent (No 5,106,621) covering the Vianain enzymatic debridement agent. Genzyme is developing the product as a treatment for patients with severe burns. The patent covers the individual enzymes, ananain and comosain, and the enzyme mixture that constitutes the active ingredient of the product. According to Genzyme, it anticipates submitting an Invest-igational New Drug Application to the US Food and Drug Administration during the second quarter of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze